Massa Silvia, Paolini Francesca, Marino Carmela, Franconi Rosella, Venuti Aldo
Biotechnology Laboratory, Biotechnology and Agroindustry Division, Department of Sustainability, ENEA (Italian National Agency for New Technologies, Energy and Sustainable Economic Development), Rome, Italy.
Virology Laboratory, HPV-UNIT, Department of Research, Advanced Diagnostic and Technological Innovation (RIDAIT), Translational Research Functional Departmental Area, IRCSS Regina Elena National Cancer Institute, Rome, Italy.
Front Plant Sci. 2019 Apr 11;10:452. doi: 10.3389/fpls.2019.00452. eCollection 2019.
Human papillomavirus (HPV) tumor disease is a critical public health problem worldwide, especially in the developing countries. The recognized pathogenic function of E5, E6, and E7 oncoproteins offers the opportunity to devise therapeutic vaccines based on engineered recombinant proteins. The potential of plants to manufacture engineered compounds for pharmaceutical purposes, from small to complex protein molecules, allows the expression of HPV antigens and, possibly, the regulation of immune functions to develop very specific therapies as a reinforcement to available nonspecific therapies and preventive vaccination also in developed countries. Among plant-based expression formats, hairy root cultures are a robust platform combining the benefits of eukaryotic plant-based bioreactors, with those typical of cell cultures. In this work, to devise an experimental therapeutic vaccine against HPV, hairy root cultures were used to express a harmless form of the HPV type 16 E7 protein (E7*) fused to SAPKQ, a noncytotoxic form of the saporin protein from that we had shown to improve E7-specific cell-mediated responses as a fusion E7*-SAPKQ DNA vaccine. Hairy root clones expressing the E7*-SAPKQ candidate vaccine were obtained upon infection of leaf explants of using a recombinant plant expression vector. Yield was approximately 35.5 μg/g of fresh weight. Mouse immunization with vaccine-containing crude extracts was performed together with immunological and biological tests to investigate immune responses and anticancer activity, respectively. Animals were primed with either E7*-SAPKQ DNA-based vaccine or E7*-SAPKQ root extract-based vaccine and boosted with the same (homologous schedule) or with the other vaccine preparation (heterologous schedule) in the context of TC-1 experimental mouse model of HPV-associated tumor. All the formulations exhibited an immunological response associated to anticancer activity. In particular, DNA as prime and hairy root extract as boost demonstrated the highest efficacy. This work, based on the development of low-cost technologies, highlights the suitability of hairy root cultures as possible biofactories of therapeutic HPV vaccines and underlines the importance of the synergic combination of treatment modalities for future developments in this field.
人乳头瘤病毒(HPV)肿瘤疾病是一个全球性的重大公共卫生问题,在发展中国家尤为突出。E5、E6和E7癌蛋白已被确认的致病功能为基于工程重组蛋白设计治疗性疫苗提供了契机。植物具有制造从小分子到复杂蛋白质分子等用于制药目的的工程化合物的潜力,这使得HPV抗原得以表达,并且有可能调节免疫功能,从而开发出非常特异性的疗法,作为对发达国家现有非特异性疗法和预防性疫苗接种的补充。在基于植物的表达形式中,毛状根培养是一个强大的平台,它结合了真核植物生物反应器的优点以及细胞培养的典型优点。在这项工作中,为了设计一种针对HPV的实验性治疗疫苗,利用毛状根培养来表达与SAPKQ融合的16型HPV E7蛋白的无害形式(E7*),SAPKQ是来自皂草素蛋白的一种无细胞毒性形式,我们已证明其作为融合E7*-SAPKQ DNA疫苗可改善E7特异性细胞介导的反应。使用重组植物表达载体感染的叶片外植体后,获得了表达E7*-SAPKQ候选疫苗的毛状根克隆。产量约为每克鲜重35.5微克。用含疫苗的粗提物对小鼠进行免疫,并分别进行免疫学和生物学测试,以研究免疫反应和抗癌活性。在HPV相关肿瘤的TC-1实验小鼠模型中,用基于E7*-SAPKQ DNA的疫苗或基于E7*-SAPKQ根提取物的疫苗对动物进行初次免疫,并用相同的疫苗制剂(同源方案)或另一种疫苗制剂(异源方案)进行加强免疫。所有制剂均表现出与抗癌活性相关的免疫反应。特别是,以DNA作为初次免疫,以毛状根提取物作为加强免疫显示出最高的疗效。这项基于低成本技术开发的工作,突出了毛状根培养作为治疗性HPV疫苗可能的生物工厂的适用性,并强调了治疗方式协同组合对该领域未来发展的重要性。